amifostine anhydrous has been researched along with Hearing Loss in 14 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective was to assess the efficacy of any medical intervention to prevent hearing loss in children with cancer treated with platinum-based therapy (that is including cisplatin, carboplatin and/or oxaliplatin) when compared to placebo, no additional treatment or a different protective medical intervention." | 4.90 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2014) |
| "At the moment there is no evidence from individual studies in children with osteosarcoma and hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment." | 2.48 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2012) |
| " Ototoxicity is an important and dose-limiting side-effect of cisplatin therapy." | 2.43 | Future opportunities in preventing cisplatin induced ototoxicity. ( Balm, AJ; Beijnen, JH; Schellens, JH; van den Berg, JH, 2006) |
| "Chemoprotective agents reduce the toxic side effects of chemotherapy agents such as cisplatin." | 1.32 | WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. ( Blakley, BW; Burgio, DL; Church, MW; Gupta, AK, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hazlitt, RA | 1 |
| Min, J | 1 |
| Zuo, J | 1 |
| Gurney, JG | 1 |
| Bass, JK | 1 |
| Onar-Thomas, A | 1 |
| Huang, J | 1 |
| Chintagumpala, M | 3 |
| Bouffet, E | 1 |
| Hassall, T | 2 |
| Gururangan, S | 2 |
| Heath, JA | 1 |
| Kellie, S | 2 |
| Cohn, R | 1 |
| Fisher, MJ | 1 |
| Panandiker, AP | 1 |
| Merchant, TE | 2 |
| Srinivasan, A | 1 |
| Wetmore, C | 1 |
| Qaddoumi, I | 1 |
| Stewart, CF | 2 |
| Armstrong, GT | 1 |
| Broniscer, A | 2 |
| Gajjar, A | 2 |
| van As, JW | 2 |
| van den Berg, H | 2 |
| van Dalen, EC | 2 |
| Fouladi, M | 1 |
| Ashley, D | 1 |
| Gronewold, L | 1 |
| Wallace, D | 1 |
| Hale, GA | 1 |
| Kasow, KA | 1 |
| Morris, B | 1 |
| Krasin, M | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Freyer, DR | 1 |
| Sung, L | 1 |
| Reaman, GH | 1 |
| Katzenstein, HM | 1 |
| Chang, KW | 1 |
| Krailo, M | 1 |
| Chen, Z | 1 |
| Finegold, MJ | 1 |
| Rowland, J | 1 |
| Reynolds, M | 1 |
| Pappo, A | 1 |
| London, WB | 1 |
| Malogolowkin, M | 1 |
| Sullivan, MJ | 1 |
| Paulino, AC | 1 |
| Lobo, M | 1 |
| Teh, BS | 1 |
| Okcu, MF | 1 |
| South, M | 1 |
| Butler, EB | 1 |
| Su, J | 1 |
| Hussain, AE | 1 |
| Blakley, BW | 2 |
| Nicolas, M | 1 |
| Balderston, J | 1 |
| Church, MW | 1 |
| Burgio, DL | 1 |
| Gupta, AK | 1 |
| van den Berg, JH | 1 |
| Beijnen, JH | 1 |
| Balm, AJ | 1 |
| Schellens, JH | 1 |
| Xiong, X | 1 |
| Tan, M | 1 |
| Boyett, J | 1 |
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
4 reviews available for amifostine anhydrous and Hearing Loss
| Article | Year |
|---|---|
Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
Topics: Animals; Cisplatin; Drug Discovery; Hearing Loss; Humans | 2018 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2014 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2012 |
Future opportunities in preventing cisplatin induced ototoxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Animals; Antineoplastic Agents; Cisplatin; Hearing Loss; Hu | 2006 |
4 trials available for amifostine anhydrous and Hearing Loss
| Article | Year |
|---|---|
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Cerebellar Neoplasms; Child; Child, Preschool; Cispla | 2014 |
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; | 2008 |
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Ci | 2009 |
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
6 other studies available for amifostine anhydrous and Hearing Loss
| Article | Year |
|---|---|
Prevention of hearing loss in children receiving cisplatin chemotherapy.
Topics: Amifostine; Child; Cisplatin; Hearing Loss; Humans; Medulloblastoma | 2009 |
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter | 2009 |
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Topics: Adolescent; Amifostine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cerebe | 2010 |
Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Evoked Potentials, Auditory, Brain Stem; Guin | 2003 |
WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Topics: Amifostine; Animals; Auditory Threshold; Cisplatin; Cochlea; Cricetinae; Disease Models, Animal; Dos | 2004 |
A sequential procedure for monitoring clinical trials against historical controls.
Topics: Amifostine; Antineoplastic Agents; Brain Neoplasms; Child; Clinical Trials as Topic; Data Interpreta | 2007 |